|
|
|
Insider
Information: |
Smith Sandford D |
Relationship: |
Director |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
386,982 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$929,055 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
386,982 |
|
|
Total
Value |
$929,055 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
7
|
Stock
price went up :
|
0
|
2
|
Stock
price went down : |
0
|
5
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-24.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Ariad Pharmaceuticals Inc |
ARIA |
Director |
2007-06-20 |
131,205 |
2004-01-15 |
0 |
Premium* |
|
Genzyme Corp |
GENZ |
Exe VP,President Intl ... |
2011-04-04 |
0 |
2005-07-29 |
0 |
Premium* |
|
Aegerion Pharmaceuticals, Inc. |
AEGR |
Director |
2016-11-29 |
0 |
2013-08-09 |
0 |
Premium* |
|
Palisade Bio Inc |
PALI |
Director |
2019-07-01 |
219,916 |
|
0 |
Premium* |
|
Seelos Therapeutics Inc |
SEEL |
Director |
2017-01-05 |
16,160 |
2014-10-22 |
0 |
Premium* |
|
Novelion Therapeutics Inc |
NVLN |
Director |
2017-01-27 |
900 |
2016-11-29 |
0 |
Premium* |
|
Cytokinetics Inc |
CYTK |
Director |
2024-01-02 |
18,801 |
2020-06-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
113 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
GENZ |
Genzyme Corp |
Executive Vice President |
|
2007-10-15 |
4 |
OE |
$46.24 |
$1,156,000 |
D/D |
25,000 |
30,112 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-04-09 |
4 |
AS |
$23.79 |
$659,990 |
D/D |
(27,582) |
920 |
0 |
% |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-04-09 |
4 |
OE |
$6.82 |
$217,822 |
D/D |
27,582 |
5,295 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-12-27 |
4 |
S |
$45.79 |
$1,295,399 |
D/D |
(28,290) |
6,765 |
0 |
% |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-12-27 |
4 |
OE |
$15.43 |
$597,150 |
D/D |
28,290 |
10,889 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-11-19 |
4 |
OE |
$9.45 |
$382,247 |
D/D |
29,032 |
10,797 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-11-19 |
4 |
S |
$41.21 |
$1,196,275 |
D/D |
(29,032) |
6,765 |
0 |
% |
|
GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
|
2010-07-23 |
4 |
OE |
$41.50 |
$1,427,082 |
D/D |
32,041 |
52,712 |
0 |
- |
|
GENZ |
Genzyme Corp |
Exe VP,President Intl Group |
|
2010-07-23 |
4 |
AS |
$63.75 |
$2,063,764 |
D/D |
(32,041) |
20,671 |
0 |
- |
|
ARIA |
Ariad Pharmaceuticals Inc |
Director |
|
2007-06-20 |
4 |
OE |
$1.50 |
$123,700 |
D/D |
45,000 |
131,205 |
0 |
- |
|
PALI |
Palisade Bio Inc |
Director |
|
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
45,046 |
50,899 |
0 |
- |
|
PALI |
Palisade Bio Inc |
Director |
|
2015-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
106,952 |
106,952 |
0 |
- |
|
PALI |
Palisade Bio Inc |
Director |
|
2019-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
166,667 |
219,916 |
0 |
- |
|
113 Records found
|
|
Page 5 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|